National Institutes of Health (NIH)

Study shows the treatment is safe, but provides no significant benefit in this group.

Effort is part of the Accelerating Medicines Partnership to enable development of effective targeted therapies.

Finding could lead to new ways to reduce complications from painful red blood cell disorder.

ACTIV-3 is a master protocol designed to allow for the study of multiple investigational agents compared to placebo in adults hospitalized with COVID-19.

Trial explores the use of the Eliquis® in patients who have been discharged from the hospital following a diagnosis of moderate-to-severe COVID-19.

NIH, NIAID, scientists, human, cerebral organoid, test, drug, Creutzfeldt-Jakob disease.

Protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika.

Researchers hope the new approach will be used as a framework for publishing studies on polygenic risk scores. .

By eliminating extraneous light, the scientists improved resolution by 33%.

“Phage” therapies offer potential strategy to combat antibacterial resistance.